文献速递血栓与止血贫血与红细胞疾病

恶性肿瘤患者血栓、出血与抗凝的竞争风险管理

Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy.
PubMed 文献 · Blood Adv · 2019-01-01

综述指出癌症患者静脉血栓栓塞(VTE)初发和复发风险均升高,抗凝期间出血风险也高于非癌症患者,血液肿瘤及强化骨髓抑制化疗相关血小板减少进一步增加出血风险。尽管近15年抗癌治疗进步,大型研究证实出血和VTE复发率仍高,管理需在抗凝与出血风险间平衡。本文通过挑战性病例阐述抗凝后复发VTE及严重血小板减少合并新发VTE的管理策略。

要点

  • 癌症患者VTE初发和复发风险均升高,抗凝后复发仍常见。
  • 癌症患者抗凝时出血风险高于非癌症患者。
  • 血液肿瘤及强化化疗相关血小板减少进一步增加出血风险。

核心结论

  • 癌症患者同时面临血栓和出血的竞争风险,抗凝管理需平衡二者。

研究设计与样本

  • 本文为综述,通过挑战性病例阐述数据稀疏场景的管理方法。

主要发现

  • 癌症患者VTE初发和复发风险高于非癌症患者。
  • 抗凝后复发性VTE常见,带来额外管理挑战。
  • 癌症患者抗凝时出血风险高于非癌症患者。
  • 血液肿瘤及强化骨髓抑制化疗相关血小板减少使出血风险增高。
  • 近15年抗癌治疗进步,但大型研究证实出血和VTE复发率仍高。

临床怎么用

  • 抗凝后复发VTE的癌症患者需个体化管理。
  • 严重血小板减少合并新发VTE的癌症患者需平衡抗凝与出血风险。

局限性

  • 复发VTE及严重血小板减少合并新发VTE等场景数据稀疏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The association between malignancy and thrombosis has been recognized for over a century and a half. Patients with cancer have an elevated risk of both initial and recurrent venous thromboembolism (VTE) compared with patients without cancer owing to cancer- and patient-specific factors. Recurrent VTE is common despite anticoagulation, presenting additional management challenges. Patients with cancer also have an increased risk of bleeding when on anticoagulants compared with patients without cancer. This bleeding risk is heightened by the thrombocytopenia common in patients with hematologic malignancies and those treated with intensive myelosuppressive chemotherapy regimens. Despite the advancements in cancer-directed therapy made over the past 15 years, numerous large studies have confirmed that bleeding and VTE recurrence rates remain high in cancer patients. Balancing the increased and competing risks of clotting and bleeding in these patients can be difficult, because management of cancer-associated thrombosis requires anticoagulation despite known increased risks for bleeding. In the context of challenging illustrative cases, this review will describe management approaches to clinical scenarios in which data are sparse: cancer patients with recurrent VTE despite anticoagulation and cancer patients with a new VTE in the setting of severe thrombocytopenia.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Al-Samkari H, Connors JM. Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancy. Blood Adv. 2019. PMID: 31770442. doi:10.1182/bloodadvances.2019000369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。